STOCK TITAN

[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Gilead Sciences (GILD) CFO Andrew D. Dickinson reported an open‑market sale of 2,500 shares of common stock at $118.08 on October 15, 2025. The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on August 29, 2024.

Following the transaction, Dickinson beneficially owns 157,055 shares, held directly.

Gilead Sciences (GILD) CFO Andrew D. Dickinson ha riportato una vendita sul mercato aperto di 2.500 azioni ordinarie a $118,08 il 15 ottobre 2025. La dichiarazione nota che la operazione è stata effettuata nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 29 agosto 2024.

Dopo la transazione, Dickinson detiene beneficiamente 157.055 azioni, detenute direttamente.

Gilead Sciences (GILD) El director financiero Andrew D. Dickinson informó de una venta en el mercado abierto de 2.500 acciones ordinarias a $118,08 el 15 de octubre de 2025. El registro señala que la operación se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 29 de agosto de 2024.

Tras la operación, Dickinson posee beneficiosamente 157.055 acciones, mantenidas directamente.

Gilead Sciences (GILD) CFO Andrew D. Dickinson은 2025년 10월 15일에 $118.08의 가격으로 2,500주 일반 주식을 공개시장 매도했다고 보고했습니다. 공시는 이 거래가 Rule 10b5-1 거래 계획에 따라 2024년 8월 29일에 채택되었습니다.

거래 후 Dickinson은 157,055주를 직접 보유합니다.

Gilead Sciences (GILD) le directeur financier Andrew D. Dickinson a signalé une vente sur le marché libre de 2 500 actions ordinaires à $118,08 le 15 octobre 2025. Le dossier indique que la transaction a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 29 août 2024.

Suite à l'opération, Dickinson détient bénéficiairement 157 055 actions, détenues directement.

Gilead Sciences (GILD) CFO Andrew D. Dickinson berichtete von einem Open-Market-Verkauf von 2.500 Stammaktien zum Preis von $118,08 am 15. Oktober 2025. Die Einreichung weist darauf hin, dass der Handel im Rahmen eines Rule 10b5-1-Handelsplans erfolgte, der am 29. August 2024 aufgenommen wurde.

Nach der Transaktion besitzt Dickinson vorteilhafterweise 157.055 Aktien, direkt gehalten.

Gilead Sciences (GILD) أفاد المدير المالي Andrew D. Dickinson بعملية بيع في السوق المفتوحة لــ 2,500 سهمًا من الأسهم العادية بسعر $118.08 في 15 أكتوبر 2025. يذكر الإفصاح أن الصفقة تمت ضمن خطة تداول Rule 10b5-1 اعتمدت في 29 أغسطس 2024.

بعد الصفقة، يملك Dickinson فائدة ملكية بنحو 157,055 سهمًا، مُحتفظًا بها مباشرة.

Gilead Sciences (GILD) 首席财务官 Andrew D. Dickinson 披露在公开市场出售了 2,500 股普通股,价格为 $118.08,日期为 2025 年 10 月 15 日。备案表明该交易是在 Rule 10b5-1 交易计划下进行,此计划于 2024 年 8 月 29 日 采用。

交易后,Dickinson 实益拥有 157,055 股,直接持有。

Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Gilead Sciences (GILD) CFO Andrew D. Dickinson ha riportato una vendita sul mercato aperto di 2.500 azioni ordinarie a $118,08 il 15 ottobre 2025. La dichiarazione nota che la operazione è stata effettuata nell'ambito di un piano di negoziazione Rule 10b5-1 adottato il 29 agosto 2024.

Dopo la transazione, Dickinson detiene beneficiamente 157.055 azioni, detenute direttamente.

Gilead Sciences (GILD) El director financiero Andrew D. Dickinson informó de una venta en el mercado abierto de 2.500 acciones ordinarias a $118,08 el 15 de octubre de 2025. El registro señala que la operación se realizó bajo un plan de negociación Rule 10b5-1 adoptado el 29 de agosto de 2024.

Tras la operación, Dickinson posee beneficiosamente 157.055 acciones, mantenidas directamente.

Gilead Sciences (GILD) CFO Andrew D. Dickinson은 2025년 10월 15일에 $118.08의 가격으로 2,500주 일반 주식을 공개시장 매도했다고 보고했습니다. 공시는 이 거래가 Rule 10b5-1 거래 계획에 따라 2024년 8월 29일에 채택되었습니다.

거래 후 Dickinson은 157,055주를 직접 보유합니다.

Gilead Sciences (GILD) le directeur financier Andrew D. Dickinson a signalé une vente sur le marché libre de 2 500 actions ordinaires à $118,08 le 15 octobre 2025. Le dossier indique que la transaction a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 adopté le 29 août 2024.

Suite à l'opération, Dickinson détient bénéficiairement 157 055 actions, détenues directement.

Gilead Sciences (GILD) CFO Andrew D. Dickinson berichtete von einem Open-Market-Verkauf von 2.500 Stammaktien zum Preis von $118,08 am 15. Oktober 2025. Die Einreichung weist darauf hin, dass der Handel im Rahmen eines Rule 10b5-1-Handelsplans erfolgte, der am 29. August 2024 aufgenommen wurde.

Nach der Transaktion besitzt Dickinson vorteilhafterweise 157.055 Aktien, direkt gehalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dickinson Andrew D

(Last) (First) (Middle)
GILEAD SCIENCES, INC.
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CA 94404

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/15/2025 S(1) 2,500 D $118.08 157,055 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.
Remarks:
/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Gilead (GILD) disclose in this Form 4?

The CFO, Andrew D. Dickinson, sold 2,500 shares at $118.08 on October 15, 2025.

Was the GILD insider trade under a Rule 10b5-1 plan?

Yes. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

How many Gilead shares does the CFO hold after the sale?

Andrew D. Dickinson beneficially owns 157,055 shares directly after the transaction.

What was the price and size of the GILD insider sale?

He sold 2,500 shares at a price of $118.08 per share.

Who is the reporting person in the GILD Form 4?

The reporting person is Andrew D. Dickinson, Gilead’s Chief Financial Officer.
Gilead Sciences Inc

NASDAQ:GILD

GILD Rankings

GILD Latest News

GILD Latest SEC Filings

GILD Stock Data

146.23B
1.24B
0.1%
90.75%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY